These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23791579)

  • 1. Multiple valvular regurgitation associated with bromocriptine therapy.
    Cautres T; Cautres M; Mohty D
    Arch Cardiovasc Dis; 2014 Oct; 107(10):579-80. PubMed ID: 23791579
    [No Abstract]   [Full Text] [Related]  

  • 2. Bromocriptine use and the risk of valvular heart disease.
    Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
    Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency of cardiac valvular regurgitation in Parkinson's disease.
    Yamashiro K; Komine-Kobayashi M; Hatano T; Urabe T; Mochizuki H; Hattori N; Iwama Y; Daida H; Sakai M; Nakayama T; Mizuno Y
    Mov Disord; 2008 May; 23(7):935-941. PubMed ID: 18398916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
    Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
    Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome.
    Worthington A; Thomas L
    Eur J Echocardiogr; 2008 Nov; 9(6):828-30. PubMed ID: 18579494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.
    Apostolakis EE; Baikoussis NG; Tselikos D; Koniari I; Prokakis C; Fokaeas E; Karanikolas M
    J Cardiothorac Surg; 2009 Nov; 4():65. PubMed ID: 19912629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of iatrogenic severe mitral regurgitation.
    D'Aloia A; Piovanelli B; Rovetta R; Bonadei I; Vizzardi E; Curnis A; Metra M
    Monaldi Arch Chest Dis; 2013 Sep; 80(3):133-6. PubMed ID: 24818320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valvular heart disease in patients taking pergolide.
    Waller EA; Kaplan J; Heckman MG
    Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valvular heart disease associated with fenfluramine-phentermine.
    Rasmussen S; Corya BC; Glassman RD
    N Engl J Med; 1997 Dec; 337(24):1773; author reply 1775. PubMed ID: 9411248
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamic drug-induced organic mitral regurgitation during exercise echocardiography following chronic exposure to ergotamine.
    Maréchaux S; Brahim YB; Ennezat PV; Delelis F; Tribouilloy C
    Int J Cardiol; 2015; 187():106-8. PubMed ID: 25828325
    [No Abstract]   [Full Text] [Related]  

  • 14. Cabergoline-related severe restrictive mitral regurgitation.
    Pinero A; Marcos-Alberca P; Fortes J
    N Engl J Med; 2005 Nov; 353(18):1976-7. PubMed ID: 16267335
    [No Abstract]   [Full Text] [Related]  

  • 15. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversible cardiac valve abnormalities with pergolide treatment].
    Calomne V; Dupuis MJ; Muller T; Kempinere F
    Rev Neurol (Paris); 2004 Jan; 160(1):81-2. PubMed ID: 14978397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can benfluorex-related heart valve disease be identified by echocardiography?
    Tribouilloy C; Rusinaru D; Andréjak M
    Arch Cardiovasc Dis; 2011 Oct; 104(10):489-92. PubMed ID: 22044700
    [No Abstract]   [Full Text] [Related]  

  • 19. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
    Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline and mitral regurgitation.
    Delgrange E
    N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.